Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $45.2 million.

  • C4 Therapeutics' Total Current Liabilities fell 16.97% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 16.97%. This contributed to the annual value of $45.2 million for FY2024, which is 5.64% up from last year.
  • Per C4 Therapeutics' latest filing, its Total Current Liabilities stood at $45.2 million for FY2024, which was up 5.64% from $42.8 million recorded in FY2023.
  • C4 Therapeutics' Total Current Liabilities' 5-year high stood at $51.2 million during FY2021, with a 5-year trough of $42.8 million in FY2023.
  • Its 3-year average for Total Current Liabilities is $44.2 million, with a median of $44.5 million in 2022.
  • As far as peak fluctuations go, C4 Therapeutics' Total Current Liabilities spiked by 30.35% in 2020, and later declined by 13.07% in 2022.
  • C4 Therapeutics' Total Current Liabilities (Yearly) stood at $43.9 million in 2020, then grew by 16.86% to $51.2 million in 2021, then decreased by 13.07% to $44.5 million in 2022, then fell by 4.00% to $42.8 million in 2023, then climbed by 5.64% to $45.2 million in 2024.